RENISUS Plants and Their Potential Antitumor Effects in Clinical Trials and Registered Patents

Marmitt et al., 2021 | Nutr Cancer | Systematic Review

Citation

Marmitt Diorge Jônatas, Bitencourt Shanna, ... Goettert Márcia Inês. RENISUS Plants and Their Potential Antitumor Effects in Clinical Trials and Registered Patents. Nutr Cancer. 2021;73(10):1821-1848. doi:10.1080/01635581.2020.1810290

Abstract

Cancer is a significant cause of morbidity and mortality. Scientific advances, coupled with potential flaws in current treatments, are driving research into the discovery of new bioactive molecules. This systematic review focused on scientific studies with clinical trials and patents registered on the National Relation of Medicinal Plants of Interest to the Unified Health System (RENISUS) plants (or derivative compounds) with antitumor potential. Studies with 19 different forms of cancer were found, the prostate being the organ with the highest research incidence and the species Glycine max, Curcuma longa, and Zingiber officinale, beside the phytochemicals curcumin and soy isoflavone were the most tested in clinical trials/patents.

Key Findings

Studies with 19 different forms of cancer were found, the prostate being the organ with the highest research incidence and the species Glycine max, Curcuma longa, and Zingiber officinale, beside the phytochemicals curcumin and soy isoflavone were the most tested in clinical trials/patents.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size See abstract
Age Range See abstract
Condition See abstract

MeSH Terms

  • Zingiber officinale
  • Humans
  • Neoplasms
  • Phytochemicals
  • Phytotherapy
  • Plants, Medicinal

Evidence Classification

  • Level: Systematic Review
  • Publication Types: Journal Article, Research Support, Non-U.S. Gov't, Systematic Review
  • Vertical: ginger

Provenance


Source extracted via PubMed E-utilities API on 2026-04-09